News Hub | News Direct

All Industries


Article thumbnail News Release

Forte Minerals Attends 92nd Annual PDAC

Forte Minerals Corp.

Forte Minerals Corp. (“Forte” or the “Company”) ( CSE: CUAU ) ( OTQB: FOMNF ) ( Frankfurt: 2OA ), is pleased to announce that the company will be attending this year's Prospectors & Developers Association of Canada (PDAC) convention, taking place in person at the Metro Toronto Convention Centre on March 3-6, 2024. Forte is a junior mining exploration company with an attractive portfolio of high-quality copper and gold assets in Perú. President and CEO Patrick Elliott and the team at Forte extend an invitation to the investor community, stakeholders, and all interested parties. Please drop by booth 2736 at the Investor Exchange Pavilion to discuss current and upcoming exploration plans. ABOUT FORTE MINERALS CORP Forte Minerals Corp. is a junior exploration company that has blended assets in partnership with GlobeTrotters Resources Perú S.A.C., focused on discovering and developing high-quality copper and gold assets in Peru. With a commitment to environmental stewardship, community engagement, and sustainable mining practices, Forte Minerals aims to generate significant value while upholding its social and environmental responsibilities. On behalf of FORTE MINERALS CORP. (signed) “ Patrick Elliott” Chief Executive Officer For further information, please contact: Forte Minerals Corp. office: 604-983-8847 info@forteminerals.co m www.forteminerals.com Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Forward-looking statements are not a guarantee of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include the continued availability of capital and financing, and general economic, market or business conditions, including the effects of COVID-19. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Contact Details Patrick Elliott, President & CEO +1 604-983-8847 info@forteminerals.com Company Website https://forteminerals.com/

February 28, 2024 06:40 AM Pacific Standard Time

Article thumbnail News Release

Mothers’ Milk Bank Announces Critical Need for Donor Milk

Mothers' Milk Bank

Mothers’ Milk Bank (MMB), the California-based nonprofit, is inviting lactating mothers to join its network of milk donors, aiming to expand its pool of contributors. This announcement comes on the heels of a new University of Iowa study on the health benefits of donated breast milk for extremely premature infants. The importance of donated breast milk has garnered international media attention in recent months after tennis champion Serena Williams shared her milk donation in a viral social media post. In response to the significant demand for human donor milk and the urgent need to support our communities' most vulnerable members, Mother’s Milk Bank is leading a comprehensive initiative to recruit new milk donors. This initiative includes "Milk Meet-Ups," providing opportunities for individuals to begin the month-long process of qualifying as milk donors. These Meet-Ups will kick off with an in-person Milk Drive on February 29 in Madera County at the Madera Department of Public Health, marking the start of an ambitious Milk Donor Drive aiming to enlist 5,000 new donors throughout 2024. Mothers’ Milk Bank Milk Meet-Up Schedule: Madera County (north of Fresno): Madera Department of Public Health Date: February 29, 2024 | Time: 10:30am - 12:30pm Location: 1604 Sunrise Ave, Madera, CA 93638 | Oz Conference Room Los Angeles County: Henry Mayo’s Lactation Department Date: March 28, 2024 | Time: TBD Location: 23861 McBean Pkwy Suite B-14 Valencia CA, 91355 VIRTUAL Milk Drive with Lucile Packard Children's Hospital Click to start the donor registration process beginning April 1, 2024 Santa Cruz County: Watsonville Community Hospital Date: May 2, 2024 | Time: 10:00am - 12:00pm Location: 75 Nielson St., Watsonville, CA 95076 | Conference Room 1 & 2 Sacramento County: McKinley Park Date: May 3, 2024 | Time: 10:00am - 1:00pm Location: 601 Alhambra Blvd, Sacramento, CA 95816 Placer County: Women’s & Children’s Center Date: May 4, 2024 | Time:10:00am - 1:00pm Location: 1600 Eureka Rd., Roseville, CA 95661 | Building B Premature infants, medically fragile babies, and those with special medical needs depend on donated breast milk for their survival. In 2023, over 2,000 generous donors contributed to Mothers’ Milk Bank, providing 1.64 million ounces of this life-saving mothers’ milk to babies in need across the United States. Recognizing the growing demand, Mothers’ Milk Bank anticipates an increased need in 2024. To meet this demand, the organization aims to recruit 5,000 lactating mothers from diverse backgrounds to become donors of this precious "liquid gold”. The process to become a donor typically takes a month, resulting in an ongoing need to recruit new donors to ensure a steady supply of donor milk. On average, most donors only send milk for less than one year or until their baby turns one, it is critical to consistently raise awareness of the importance of donating surplus mothers’ milk. “We are experiencing a pressing need for more milk donors, and it's vital for the welfare of the infants depending on our services that we expand our donor network without delay," states Jennifer Benito-Kowalski, chief executive officer of Mothers' Milk Bank. Mothers who are currently breastfeeding and have excess milk are encouraged to consider donating to help fill this crucial need. To start the process, visit the Mothers’ Milk Bank website to fill out an application. Those who are unable to donate breast milk can still help by sponsoring a cooler for $98 or by making a financial contribution. Why donate breast milk? The need for donated breast milk remains constant, especially for infants facing health complications. According to the National Institute of Health, more than 300,000 babies require advanced medical care in neonatal intensive care units across the United States every year. This need may arise when infants are born prematurely before their mother's milk has developed, when they face specific health challenges during infancy, or when they are adopted or born through surrogacy. Eligible milk donors include lactating mothers whose bodies produce more milk than their own baby needs, when they have lost their own child postpartum and need to help their body transition from lactation, or simply because they are altruistically driven to support infant health through equal access to breast milk. How does milk donation work? Mothers’ Milk Bank screens all potential breast milk donors through a comprehensive but easy, facilitated process per internationally recognized guidelines. All donated milk is pooled, pasteurized and tested before distribution to hospitals and families in need. There is no cost to becoming a milk donor – nor are donors compensated. Mothers’ Milk Bank provides donors with professional support and resources during the donation process and covers all screening and shipping costs. Lactating mothers interested in becoming a donor can learn more about the Milk Meetups and Spring Donor Drive at MothersMilk.org. To get started send an email to donate@MothersMilk.org, call 1-877-375-6645, Ext. 3 or apply online. *** To schedule an interview, contact Liza Batallones at 415-766-0846 or liza@landispr.com. Hi-res images are available for download here. About Mothers’ Milk Bank Founded nearly 50 years ago, the Mothers’ Milk Bank is a leading nonprofit organization based in San Jose, California, that is dedicated to providing screened, donated human milk to all babies. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families in need, ensuring that infants receive the essential nutrition required for optimal health and development. With a commitment to improving the lives of babies, Mothers’ Milk Bank plays a vital role in supporting families and advancing neonatal care across California and beyond. More information at MothersMilk.org. Contact Details Landis Communications, Inc. Liza Batallones +1 415-766-0846 liza@landispr.com Company Website https://mothersmilk.org/

February 28, 2024 06:00 AM Pacific Standard Time

Image
Article thumbnail News Release

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC

Kadimastem

In accordance with the MOU, Kadimastem will provide IMCC a loan of up to $650,000, which will be used by IMCC to restructure its current operations for sale allow Kadimastem to enter the public platform on the NASDAQ Kadimastem Ltd. (TASE: KDST), a leading cell therapy company in the clinical development stages of breakthrough products for the treatment of ALS and diabetes, has completed another step on the way to signing a merger with the U.S. NASDAQ listed company IMCC; IM Cannabis Corp (“IMCC”), (which is also listed in Canada on the CNSX) as reported several weeks ago, thus becoming a Nasdaq-listed company. The Company signed a loan agreement with IMCC, in accordance with their MOU. The loan amounts up to about $650,000 with the goal of organizing the current IMCC operations and preparing it for sale under a contingent value right (CVR) to be distributed to IMCC record shareholders prior to the consummation of the merger with Kadimastem', hence allowing Kadimastem to enter into IMCC’s public platform on the NASDAQ without taking ownership of IMCC’s current operations. Once and subject to the completion of the merger transaction and signing of the definitive documentation, pursuant to the MOU Kadimastem shareholders are expected to hold 88% of the shares of the combined company post -merger upon which Kadimastem will no longer be trading on the Tel Aviv Stock Exchange. The MOU is in line with the Company's strategic plan, to approach the target markets of its field of activity and the US capital markets. As part of the terms of the MOU, Kadimastem undertook to have approximately $5 million in funds, including capital raised simultaneously with the completion of the transaction and the commencement of trading from existing shareholders and additional investors. Ronen Twito, Executive Chairman of the Board said, "We are moving one step further towards a merger deal with IMCC that is planned to enable us to trade on the NASDAQ. This will assist Kadimastem’s development in the US capital markets especially in view of FDA approval to start a phase IIa multi-site clinical trial in the US for the ALS product candidate, as well as our development plans for additional product candidates, and especially the diabetes product candidate. I believe that together with IMCC’s professional management we will be able to promote the transaction quickly and professionally and generate significant value to our shareholders upon completion of the transaction." Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. Kadimastem was founded in 2009 based on patent protected technology that was developed at Prof. Michel Revel’s laboratory at the Weizmann Institute of Science. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

February 28, 2024 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Backpack Raises $17 Million Strategic Series A Round Led by Placeholder VC

Backpack

The Backpack ecosystem of companies, creators of the Backpack wallet, the Mad Lads NFT collection, and Backpack Exchange, today announced the first joint closing of their $17 million strategic Series A round at a $120 million combined valuation. The round was led by Placeholder VC, with participation from a select group of other strategic investors including Hashed, Robot Ventures, Amber Group, Wintermute, Selini Capital, Delphi Digital, and founders of leading web3 ecosystems such as Solana, Tensor, Jito, Zeta, Marginfi, Drift, Monad, Galxe, and other influential supporters worldwide. Armani Ferrante, CEO of Backpack commented on the news: “The history of finance is littered with scandals, but Backpack is doing things differently. Over the past year, we've set the foundation to build a crypto-native financial institution, and with the conclusion of this round, with trust minimization and compliance as foundational principles, we begin a new chapter for ourselves and, hopefully, for the rest of the industry.” The Backpack ecosystem comprises several products and services, including the popular Backpack noncustodial wallet, Backpack Exchange, a fully regulated global cryptocurrency exchange with industry-leading speed, security and functionalities, and Mad Lads, currently the top NFT community in the Solana ecosystem. Backpack is also the creator and developer of Anchor, the Solana smart contract framework, the executable NFT (xNFT) token standard, and others. Backpack’s strategic fundraising was led by Placeholder VC. “We’ve been impressed with Backpack’s ability to not only deliver high-quality applications, but also build a strong community around their ecosystem,” said Joel Monegro, General Partner at Placeholder VC. “After building a relationship with the team over the past year, we’re convinced they have the skill, ambition and drive to create one of the most trustworthy global exchanges in the industry with a strong focus on performance, compliance, and auditability.” "The Backpack team is an all-star team that really understands the community with a focus on building compliant services. Their ability to create the best user experience is top notch, and the synergies within their ecosystem are evidenced by their strong track record of user acquisition within the industry to date." Baek Kim, General Partner at Hashed said. "We are very excited to work with the team and resonate deeply with their compliance standpoint in terms of being optimally regulated and entering the mainstream of the global financial infrastructure." The round also attracted strong interest from other leading web3 ecosystem players. “The Backpack team is a great example of what happens when crypto natives are also strong builders. They understand that crypto is not just the underlying technology, it is also the culture that forms around it,” said Evgeny Gaevoy, founder of Wintermute, one of the largest liquidity providers in digital assets, “For me, Backpack is having the success I would expect, when a team figures out the intersection of tech and culture. I’m excited to see them continue to grow.” Backpack’s fundraising was applauded by the Solana ecosystem as well. “Backpack has not only pioneered exceptional products such as the Backpack Wallet but has also cultivated a remarkable community through the Mad Lads. Armani and the Backpack team have exemplified what it means to focus on great products and user experiences and iterate relentlessly,” said Anatoly Yakovenko, founder of Solana Labs, “Watching Backpack build a global exchange that stands out for its user experience and trustworthiness has been truly inspiring.” About Backpack Wallet Backpack Wallet is an all-in-one web3 app that functions as a noncustodial wallet, allowing users to buy, hold, sell, and transfer cryptocurrencies, as well as interact with xNFTs, a popular NFT standard that tokenizes applications. Backpack Wallet is also the creator of Mad Lads, the top NFT collection in the Solana ecosystem. For additional information on Backpack Wallet, visit https://www.backpack.app/. About Backpack Exchange Backpack Exchange is a fully regulated global cryptocurrency exchange innovating to provide an exciting, fun, and easy-to-use trading platform for both experienced and new web3 users worldwide. For more information, visit backpack.exchange. Twitter https://twitter.com/Backpack Youtube https://www.youtube.com/@BackpackExchange LinkedIn https://www.linkedin.com/company/backpackexchange/ Contact Details Backpack Qimei Luo press@backpack.exchange

February 28, 2024 08:58 AM Eastern Standard Time

Video Image
Article thumbnail News Release

Nestle Brands Reinforce Commitment to Esports Through New Sponsorship Deals

MarketJar

Maggi, one of Nestle’s billion-dollar brands, and its oriental noodles brand Fusian continue their support for the esports industry by extending their sponsorship with GiantX. 1 This partnership, now entering its fourth year, solidifies Maggi Fusian as the official partner of one of Europe's most popular and successful esports teams, GiantX. GiantX, formed from Giants Gaming and Excel Esports' merger in December 2023, is a major player in esports, excelling in various video game titles. It's a key founder of two major leagues - League of Legends EMEA Championship (LEC) and Valorant Champions Tour EMEA (VCT) by Riot Games. With headquarters in London, Malaga, and Berlin, GiantX has amassed over 23 million fans in Europe. Maggi Fusian's involvement in esports began in 2021 and has since become a recognized brand in the sector alongside GiantX. This partnership highlights Maggi Fusian's commitment to the esports community and its support for GiantX in their competitive endeavors. GiantX also signed a partnership agreement with KitKat, another Nestle company. In January, the partnership was renewed for an additional year. 2 As per the renewed partnership agreement, KitKat's logo will appear on the sleeve of player jerseys during both international and domestic competitions. Additionally, KitKat's branding will be showcased on GiantX's social media and streaming channels, including YouTube and Twitch, as well as other platforms where the team shares content. The collaboration will also involve the creation of original content. Another major player in the esports market is OverActive Media (TSXV:OAM) (OTC:OAMCF), an esports and entertainment company catering to today’s generation of fans. Over the last few months, OverActive Media has solidified its position as a major player in the esports world by acquiring two widely popular esports franchises, gaining new major sponsors and increasing both its audience engagement and viewership statistics across the leading streaming and social media platforms. Partnerships With Brands Drive Esports Growth Since adding KOI and Movistar Riders to its portfolio, OverActive Media has seen a significant uptick in viewership thanks to the popularity of the teams which have over 100 million dedicated followers and the social media cred of its co-founders Ibai Llanos, a world-leading Twitch streamer and former FC Barcelona football legend Gerard Piqué. OverActive Media has seen its viewer numbers soar in games like League of Legends, VALORANT, Counter Strike 2, and Call of Duty. The Mad Lions KOI team's performance, drawing a record 741,000 viewers in one match and 4.7 million Twitch views thanks to Ibai, has outshined even top TV show finales. In January, MAD Lions KOI and Movistars led the esports category in viewership and total engagements across major social media platforms in Europe and North America. It was also a top five brand globally during the same period. Their success continued with a historic 830,816 viewers for a single match, surpassing average NHL game viewerships. “Our ability to captivate a massive, global audience is pivotal to our success. The immediate surge in engagement and viewership after announcing the acquisitions highlights the strategic value of our operations and solidifies our leadership in the esports industry," said OverActive Media CEO Adam Adamou. "Merging our existing business with these acquisitions opens new vistas for viewer engagement. The enthusiastic response from our fans and partners reaffirms our direction and commitment.” The company has also bolstered its portfolio of noteworthy partnerships. On February 28, OverActive Media (TSXV:OAM) (OTC:OAMCF) announced a multi million dollar sponsorship with Telefónica, one of the largest telephone operators and mobile network providers in the world. Telefónica, which is a long-time partner of Movistar Riders, renewed its sponsorship for three years to the end of 2026. The expanded partnership includes select naming rights, brand visibility on team gear and products, and collaborative content development and marketing. In 2022, Telefónica took a minority stake in Movistar Riders. With the completion of these acquisitions, Telefónica will transition to becoming a shareholder in OverActive Media. Telefónica is the latest addition to OverActive Media ’s roster of partnerships which includes respected brands including Bell, who is also a shareholder of the company, as well as Kappa, Red Bull, TD, Razer, SCUF and AMD. Click here for more information about OverActive Media (TSXV:OAM) (OTC:OAMCF). [1] https://europeangaming.eu/portal/latest-news/2024/02/22/153417/maggi-renews-its-sponsorship-with-giantx/ [2] https://esportsadvocate.net/2024/01/giantx-renews-partnership-with-kitkat/ Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, OverActive Media. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by OverActive Media’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by OverActive Media’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-oam. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding OverActive Media’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to OverActive Media’s industry; (b) market opportunity; (c) OverActive Media’s business plans and strategies; (d) services that OverActive Media intends to offer; (e) OverActive Media’s milestone projections and targets; (f) OverActive Media’s expectations regarding receipt of approval for regulatory applications; (g) OverActive Media’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) OverActive Media’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute OverActive Media’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) OverActive Media’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) OverActive Media’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) OverActive Media’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of OverActive Media to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) OverActive Media’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact OverActive Media’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing OverActive Media’s business operations (e) OverActive Media may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, OverActive Media undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does OverActive Media nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither OverActive Media nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of OverActive Media or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of OverActive Media or such entities and are not necessarily indicative of future performance of OverActive Media or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

February 28, 2024 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

Knightscope (NASDAQ: KSCP) Achieves Major Milestone As It Becomes An Approved Provider For the U.S. Federal Government

Benzinga

By Faith Ashmore, Benzinga While crime has always existed in human society, the scale and threat of crime can arguably rise higher with advancements in technology. Just as how we fight wars has changed, so have the methods of crime. The economic cost of crime is astronomical; in the U.S. the cost of crime is over $2.5 trillion in a single year. Studies have shown that violent crimes against young people have also been rising. When looking at crime rates and the communal cost, it's important to think about how modern technology can be implemented in solutions. Knightscope (NASDAQ: KSCP), a technology company ushering in the dawn of Autonomous Security Robots (ASRs), has spent the last decade demonstrating the potential of robots in security to the country through a large-scale proof of concept. The company currently has a suite of products ranging from stationary Blue Light emergency systems to self-driving ASRs. The CEO of Knightscope, William Santana Li, has shared that the long-term goal is to build a wide range of technologies encompassing incognito small devices to robots that can patrol cities, highways – and everything in between. The CEO believes the company has completed phase 1 of the company’s mission with over $30 million in lifetime revenue, as well as contracts across the country. The company has cemented phase 1 with the announcement of a major milestone by receiving its Authority to Operate (“ATO”) from the Federal Risk and Authorization Management Program (“FedeRAMP”), which is sponsored by the U.S. Department of Veterans Affairs. This achievement means that Knightscope will eventually be listed as an approved provider for federal agencies. The company can now also begin its deployment process to perform on the contract awarded by the VA. “Knightscope’s ATO achievement proves our organizational focus on cyber security and our unwavering commitment to our mission of better securing our country… We believe going through this intense and rigorous process has improved our security posture, which also will positively impact commercial and civilian applications,” shared Mercedes Soria, EVP and Chief Intelligence Officer, who led the nearly 3-year effort in reaching the key milestone. CEO Li believes that with this milestone accomplished, the company is firmly on its way through phase 2 of the company’s growth, with a focus on sustained and increased profitability. The major goals of Knightscope's phase 2 are focused on improving organizational efficiency, increasing margins, introducing new products and technologies and exploring potential acquisitions. To achieve these goals, the company aims to streamline management decision-making, reduce fixed costs, consolidate purchasing activities, re-engineer its supply chain and redesign systems and subsystems. Knightscope has set targets for margins on its K1B portfolio and ASRs and plans to scale up its operations to achieve profitability by the end of the year. Knightscope is also actively pursuing the development of new products, such as the K7 ASR for private roads and properties, and exploring potential acquisitions in the autonomous vehicle space. The company hopes that these efforts will effectively accelerate technology and product development towards a future that brings the K10 ASR into production faster for autonomous patrol of cities and highways. Becoming a federal supplier means that the company’s market has now been extended beyond city and neighborhood authorities to the federal government – in Fiscal Year 2022, the federal government committed about $694 billion to contracts. Ten years ago, the idea of robots being instrumental in public safety was an idea for the big screen but not yet tangible. Knightscope seems to have successfully demonstrated the efficacy of robotics and is looking to expand its presence in phase 2. The company seems well positioned to be a major force in the robotics market, which was valued at $31.38 billion in 2021 and is expected to reach $110.39 billion by 2030 with a CAGR of 15% from 2022-2030. Click here to read more about the company’s future plans from CEO William Santana Li Photo by Knightscope Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 28, 2024 08:25 AM Eastern Standard Time

Image
Article thumbnail News Release

Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Candel Therapeutics

By Jeremy Golden, Benzinga A clinical-stage biopharmaceutical company has been granted Fast Track Designation by the FDA for a first-in-class drug candidate. Focused on developing multimodal biological immunotherapies to help patients fight cancer, Candel Therapeutics, Inc. (NASDAQ: CADL) was granted the designation for CAN-3110, a replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate for patients with recurrent high-grade glioma (HGG). The Needham, Mass.-based company hopes CAN-3110 will improve overall survival in this patient population. A phase 1b clinical trial of CAN-3110 in recurrent HGG, led by E. Antonio Chiocca, MD, PhD, Head of the Department of Neurosurgery at Brigham & Women’s Hospital and Professor at Harvard Medical School, is ongoing. Candel Therapeutics plans to report additional data, including the potential benefits from multiple injections of CAN-3110, from the clinical trial in the second half of 2024. Designed to facilitate the development and expedite the review of medicines that can treat serious conditions, Fast Track Designation offers an investigational medicine eligibility for more frequent interactions with the FDA to discuss the candidate’s development plan. The medicine may be eligible for priority review if relevant criteria are met. “Receiving FDA Fast Track Designation for CAN-3110 reinforces the critical need to find effective treatment options for patients with recurrent HGG and further supports the potential of CAN-3110 to address the challenges that the standard of care and conventional therapies have failed to meet,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. “A strong local and systemic anti-tumoral response and improved survival in patients with recurrent HGG was observed following a single injection of CAN-3110 in the Phase 1b trial.” Additionally, Candel and academic collaborators at the Brigham and Women’s Hospital published results from the ongoing phase 1b clinical trial in the high-impact journal Nature, demonstrating that CAN-3110 was well tolerated with no dose-limiting toxicity reported. The investigators observed a near-doubling of the expected median overall survival (mOS) after a single CAN-3110 injection, achieving a mOS of about 12 months, compared to historical reports of less than 6 to 9 months in this therapy-resistant condition. Positive HSV-1 serology was a predictor of response and was associated with improved survival; the mOS in this population reached 14 months. 50 to 80% of American adults have oral herpes (HSV-1), which causes cold sores or fever blisters near or in the mouth. Caused by HSV-1 or HSV-2, genital herpes affects one out of every six people in the U.S. aged 14 to 49. Furthermore, increased infiltrating immune cells in the tumor microenvironment and expansion of the T cell repertoire after administration were also associated with improved survival, suggesting that CAN-3110 can elicit both a local and systemic antitumoral response. “Recurrent HGG is one of the most aggressive malignancies for which there is no cure, representing a significant and urgent unmet need,” Chiocca, the study director, said. “With Fast Track Designation, I look forward to the potential of accelerating the development of CAN-3110 and the possibility of bringing this differentiated therapy to patients with recurrent high-grade glioma as we strive to improve outcomes and provide hope for patients and their families.” In December 2023, Candel Therapeutics also received Fast Track Designation for both non-small cell lung cancer (NSCLC) and pancreatic cancer, a validation from the FDA on the potential of CAN-2409, its most advanced product candidate. An investigational viral immunotherapy, CAN-2409 is designed to stimulate an individualized, systemic immune response to the patient’s specific tumor. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC. Featured photo by Hush Naidoo Jade Photography on Unsplash. Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. This article includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Aljanae Reynolds +1 617-916-5445 areynolds@wheelhouselsa.com Company Website https://www.candeltx.com/

February 28, 2024 08:15 AM Eastern Standard Time

Image
Article thumbnail News Release

Lithium Chile Announces Favorable Results at New Arizaro Exploration Hole

Lithium Chile Inc.

CALGARY, ALBERTA – TheNewswire - February 28, 2024 – Lithium Chile Inc. (TSXV:LITH) (OTC:QB) (“ Lithium Chile ” or the “ Company ”) is pleased to provide an operational update on its Salar de Arizaro Project in Argentina, highlighting significant progress on the Company’s northeastern claims including sampling results from hole ARDHH-08. HIGHLIGHTS: One diamond drill hole was completed at the Arizaro Project: The hole encountered brine rich formations in areas not previously drilled.  Results from drilling provide for potential significant resource upside.  A new diamond drill hole, ARDDH-9 is currently underway.    ARGENTINA OPERATIONS - ARIZARO PROJECT:   ARDDH-08 has been drilled to a depth of 606-metres with a brine-rich, sandy formation encountered at 200 - metres. The bailer samples sent to Alex Stewart Laboratory, Jujuy, Argentina reported the following grades: 50-metres encountered grades of 180 mg/l Li   200-metres encountered grades of 690 mg/l Li     Results from hole ARDHH-08 represent important exploration progress for the northeastern portion of the TOLAR 6 property, where the Company does not have any mineral resource estimates contributing to the previously reported 3,342,000 tonne lithium carbonate equivalent resource associated with the project.  Due to the variability in lithium grades encountered, additional depth-specific sampling of the brines have been recommended by the Qualified Person overseeing the project.   Salar de Arizaro, Argentina: Resource Calculation Steve Cochrane, President & CEO, remarked, "The results from this new hole signify an important step in our strategic roadmap, propelling us closer towards maximizing the full potential of our claims. We are confident in the Arizaro project's potential to become a premier lithium carbonate producer, and we're energized by the promise of continued progress."   Lithium Chile’s President for South America, José de Castro, says: "We are immensely proud of our exceptional team in Argentina, whose unique experience in previous lithium projects has been instrumental in creating value for all stakeholders including the communities we work with. As we continue to progress towards a revised resource report and feasibility study to support production economics, we remain steadfast in our mission to add value and realize the full potential of the Arizaro project."   QUALIFIED PERSON, QA/QC STATEMENTS: Leandro Sastre has reviewed and approved the scientific and technical content of this news release. Mr. Sastre is a geology professional with over 20 years of experience in the international mining sector. Leandro has worked extensively throughout Latin America with a focus on Argentina, Chile and Peru.   ABOUT LITHIUM CHILE: Lithium Chile is an exploration and lithium resource company with a property portfolio consisting of 111,978 hectares in Chile and 29,245 hectares in Argentina. The Company has filed its NI 43-101 Report and Preliminary Economic Assessment, which can be viewed on the Company’s profile at SedarPlus.ca Lithium Chile also owns 5 properties totaling 22,529 hectares that are prospective for gold, silver and copper. Lithium Chile’s common shares are listed on the TSX-V under the symbol “LITH” and on the OTC-QB under the symbol “LTMCF”. To find out more about Lithium Chile, please contact Steven Cochrane, President and CEO via email: steve@lithiumchile.ca or Michelle DeCecco, Vice President and COO via email:.   NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. FORWARD LOOKING STATEMENTS: This news release may contain certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"),. Generally, forward-looking statements can be identified using forward-looking terminology such as "expected", "anticipated", "aims to", "plans to" or "intends to" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Such forward-looking statements are based on various assumptions and factors that may prove to be incorrect, including, but not limited to, factors and assumptions with respect to the general stability of the economic and political environment in which the Company operates and the timely receipt of required regulatory approvals.  You are cautioned that the foregoing list of material factors and assumptions is not exhaustive. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Lithium Chile's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Lithium Chile believes that the assumptions and factors on which such forward-looking statements are based upon reasonable assumptions, undue reliance should not be placed on the forward-looking statements because Lithium Chile can give no assurance that they will prove to be correct or that any of the events anticipated by such forward-looking statements will transpire or occur, or if any of them do, what benefits Lithium Chile will derive therefrom. Lithium Chile does not undertake to update any forward-looking statements herein, except as required by applicable securities laws. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

February 28, 2024 08:03 AM Eastern Standard Time

Image
Article thumbnail News Release

Lithium Chile Announces Favorable Results at New Arizaro Exploration Hole

Lithium Chile Inc.

CALGARY, ALBERTA – TheNewswire - February 28, 2024 – Lithium Chile Inc. (TSXV:LITH) (OTC:QB) (“ Lithium Chile ” or the “ Company ”) is pleased to provide an operational update on its Salar de Arizaro Project in Argentina, highlighting significant progress on the Company’s northeastern claims including sampling results from hole ARDHH-08. HIGHLIGHTS:   One diamond drill hole was completed at the Arizaro Project:  The hole encountered brine rich formations in areas not previously drilled.  Results from drilling provide for potential significant resource upside.  A new diamond drill hole, ARDDH-9 is currently underway.    ARGENTINA OPERATIONS - ARIZARO PROJECT:   ARDDH-08 has been drilled to a depth of 606-metres with a brine-rich, sandy formation encountered at 200 - metres. The bailer samples sent to Alex Stewart Laboratory, Jujuy, Argentina reported the following grades: 50-metres encountered grades of 180 mg/l Li   200-metres encountered grades of 690 mg/l Li     Results from hole ARDHH-08 represent important exploration progress for the northeastern portion of the TOLAR 6 property, where the Company does not have any mineral resource estimates contributing to the previously reported 3,342,000 tonne lithium carbonate equivalent resource associated with the project.  Due to the variability in lithium grades encountered, additional depth-specific sampling of the brines have been recommended by the Qualified Person overseeing the project.   Salar de Arizaro, Argentina: Resource Calculation Steve Cochrane, President & CEO, remarked, "The results from this new hole signify an important step in our strategic roadmap, propelling us closer towards maximizing the full potential of our claims. We are confident in the Arizaro project's potential to become a premier lithium carbonate producer, and we're energized by the promise of continued progress."   Lithium Chile’s President for South America, José de Castro, says: "We are immensely proud of our exceptional team in Argentina, whose unique experience in previous lithium projects has been instrumental in creating value for all stakeholders including the communities we work with. As we continue to progress towards a revised resource report and feasibility study to support production economics, we remain steadfast in our mission to add value and realize the full potential of the Arizaro project."   QUALIFIED PERSON, QA/QC STATEMENTS: Leandro Sastre has reviewed and approved the scientific and technical content of this news release. Mr. Sastre is a geology professional with over 20 years of experience in the international mining sector. Leandro has worked extensively throughout Latin America with a focus on Argentina, Chile and Peru.   ABOUT LITHIUM CHILE: Lithium Chile is an exploration and lithium resource company with a property portfolio consisting of 111,978 hectares in Chile and 29,245 hectares in Argentina. The Company has filed its NI 43-101 Report and Preliminary Economic Assessment, which can be viewed on the Company’s profile at SedarPlus.ca Lithium Chile also owns 5 properties totaling 22,529 hectares that are prospective for gold, silver and copper. Lithium Chile’s common shares are listed on the TSX-V under the symbol “LITH” and on the OTC-QB under the symbol “LTMCF”. To find out more about Lithium Chile, please contact Steven Cochrane, President and CEO via email: steve@lithiumchile.ca or Michelle DeCecco, Vice President and COO via email:.   NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. FORWARD LOOKING STATEMENTS: This news release may contain certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"),. Generally, forward-looking statements can be identified using forward-looking terminology such as "expected", "anticipated", "aims to", "plans to" or "intends to" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Such forward-looking statements are based on various assumptions and factors that may prove to be incorrect, including, but not limited to, factors and assumptions with respect to the general stability of the economic and political environment in which the Company operates and the timely receipt of required regulatory approvals.  You are cautioned that the foregoing list of material factors and assumptions is not exhaustive. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Lithium Chile's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Lithium Chile believes that the assumptions and factors on which such forward-looking statements are based upon reasonable assumptions, undue reliance should not be placed on the forward-looking statements because Lithium Chile can give no assurance that they will prove to be correct or that any of the events anticipated by such forward-looking statements will transpire or occur, or if any of them do, what benefits Lithium Chile will derive therefrom. Lithium Chile does not undertake to update any forward-looking statements herein, except as required by applicable securities laws. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

February 28, 2024 08:01 AM Eastern Standard Time

Image
1 ... 381382383384385 ... 3755
News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2024 News Direct Corp. All rights reserved. News Direct is a registered trademark.